Martin Kenny

Self-Guided Fund Manager I Family Offices & Institutional Investors I ASEAN I Tomahawk Capital for US IndividualsOverviewWe offer a strategic opportunity for biotech businesses to significantly increase the value of their business through our roll-up strategy. By consolidating multiple businesses and leveraging the higher PE ratios of publicly traded companies, owners can achieve a much higher exit valuation than selling independently.Key Points of the Value PropositionSubstantially Higher Exit Valuation:Private Market Sale Value: Typically, businesses are valued at around 5x EBITDA when sold privately.Public Market Exit Value: Through our roll-up strategy, your business(es) can be part of a larger entity valued at 40x EBITDA in the public market.Calculation of Potential Gains:Current Value of Your Business:If sold privately: $1 million EBITDA * 5 = $5 million.Value Through Our Roll-Up Strategy:Public market valuation: $1 million EBITDA * 40 = $40 million.Upside Created:Public market valuation - private market valuation = $40 million - $5 million = $35 million.Shared Upside:Your Share of the Upside:We offer you 50% of the $35 million upside.Your share = 50% * $35 million = $17.5 million.Total Value to You:Initial private sale value + your share of the upside = $5 million + $17.5 million = $22.5 million.Comparison:Private Sale:Valuation = $5 million.Through Our Roll-Up:Total valuation = $22.5 million.This represents a 4.5x higher return ($22.5 million / $5 million).Illustrative Breakdown:Private Sale:You receive $5 million.With Our Roll-Up:Initial private valuation: $5 million.Plus 50% of the upside ($17.5 million).Total: $22.5 million.Outcome:Gain an extra $17.5 million.Equivalent to a 4.5x higher return.Additional Benefits:Reduced Risk: Gains are aligned with actual market performance, reducing your financial risk.Professional Management: Benefit from experienced management and operational efficiencies.Strategic Growth: Enhanced growth prospects through combined resources and synergies.Simple TermsSell Privately: Receive $5 million.Join Our Roll-Up: Receive $22.5 million.Extra Gain: $17.5 million.Return: 4.5x higher.ConclusionBy partnering with us, you can maximize your business's value through our roll-up strategy. This ensures a strong initial valuation and significant participation in the upside of the public market, resulting in a much higher exit valuation. Would you prefer to sell your practice for $5 million or for $22.5 million? Join us and transform your biotech business’s valuation today.